#883: How to Legalize Medical Psychedelics in Your Country — Tania de Jong on The Playbook Behind Australia's World-First Breakthrough

Why does it matter? Because one outsider with a song and a cold-email strategy just handed every other country a roadmap.

Australia became the first country in the world to legalize medical psychedelics not through pharma lobbying or government science, but because an entrepreneur-singer with no drug history cold-emailed her way to the world's top researchers, trained 750 clinicians, and flooded a regulator with 13,000 public submissions. The decisive moment wasn't a clinical trial. It was a widow's testimony that left 140 government employees unable to speak.

• The TGA predicted 10-15 attendees at its key meeting; 140 showed up — and the room went silent before a single data slide appeared • The hardest opposition wasn't government or pharma: it was researchers with funding incentives to keep studying the same questions for another decade • Real-world Australian data shows 60-80% remission rates versus 10-15% for existing treatments — and unlike antidepressants, remission keeps rising after treatment ends • The $15,000 AUD cost of a full course has almost nothing to do with the drug itself — it's therapist hours, and group formats could solve that

A widow's two sentences did what years of data could not

140 people showed up to a meeting the TGA's own head expected 10 or 15 to attend. That number alone says something about what Mind Medicine Australia had built by late 2022. What happened inside explains the approval.

Before Professor David Nutt presented his data to the assembled Department of Health staff, a woman named Vanessa spoke. Her husband Franco had developed severe depression without warning — no previous history, sudden onset. She'd kept a 20-page dossier of every treatment they'd attempted: institutions, professors, every drug combination available. Nothing worked. He wasn't stable enough to travel to the Netherlands for legal psilocybin therapy. He didn't want to go underground in Australia.

She told the room: "I believe that if my husband had had access to these treatments, he might still be alive today. I believe our young daughter would still have a father."

There wasn't a dry eye in the room. Then Nutt walked up and presented the science.

The order mattered enormously. Vanessa's testimony created the emotional permission for bureaucrats to act on data they had already reviewed — and rejected — twice. MMA had spent years presenting at webinars, building chapters across 30 cities, training clinicians, assembling a 75-person advisory panel. The TGA had knocked the application back at interim stage in two separate submissions. Two sentences moved what none of that had.

Lead with one specific human story before the slides. That's the instruction this episode gives everyone running an advocacy campaign.

The five-prong playbook that forced a regulator's hand

Thirteen thousand Australians submitted public comments supporting rescheduling — over 98% in favor. It remains the largest public submission response the TGA has ever received for any medicine rescheduling, and the regulator was legally required to publish every single one.

That volume doesn't self-generate. Mind Medicine Australia had spent years building the infrastructure to produce it: 30+ community chapters from Byron Bay to Darwin to Perth, with templates and trained volunteers running local campaigns. Thousands of presentations to politicians, business leaders, and health professionals. Webinars educating the public while the application wound through bureaucracy.

Running in parallel: a 75-person world-leading advisory panel; a certificate in psychedelic-assisted therapy that had trained over 750 clinicians — psychiatrists, psychologists, nurses, occupational therapists — who then pressured their own professional peak bodies; a roadshow with Professor David Nutt through packed town halls and black-tie philanthropy events; and lobbying firm Hawker Britton navigating Canberra's internal dynamics.

And: Tania had the mobile number of the TGA's head.

"I was lucky to have that," she says, with characteristic understatement. When submissions were delayed or procedural obstacles materialized, she could call.

Countries attempting this without all five prongs running simultaneously are likely to stall. Each reinforces the others — trained clinicians create professional credibility; public chapters create political noise; the advisory panel repels scientific dismissal. Sequence them, and you lose.

The people who fought hardest against rescheduling were getting paid to keep researching

"We had people literally confront us. It was very, very vicious and personal."

The opposition Tania and Peter hadn't anticipated wasn't government resistance or pharmaceutical lobbying. It was researchers — specifically, researchers with active funding to study psilocybin and MDMA who did not want the questions closed.

MMA's argument was precise: dozens of trials had already replicated these results across multiple markets. Replicating them again for another five to ten years while patients exhausted every other option and took their own lives was not caution. It was job security.

One researcher who had run an MDMA trial with four patients — a study that took more than five years to complete — became one of their most aggressive opponents. The attacks turned personal.

There was also a credentialing front. Because neither Tania nor Peter were clinicians, segments of the field felt entitled to dismiss them entirely: "Who are these people? How dare they come into our space?"

Their structural response: always appear alongside clinicians when presenting to professional audiences. Fund novel research — eating disorders, OCD — to demonstrate genuine commitment to science rather than just regulatory shortcuts. Build the advisory panel large enough that no one could credibly question the scientific weight behind MMA's position.

Before launching any similar campaign, map the incentive structures of every stakeholder group. What presents as scientific caution sometimes has a salary attached.

60-80% remission rates — and they keep rising after the sessions end

Sixty to eighty percent remission. That's what Australia's first 400 real-world patients are showing — compared to 10-15% for existing PTSD and depression treatments — with zero serious adverse events reported to the TGA.

This is not a controlled trial with hand-selected participants. These are 20-plus authorized clinics treating people who have exhausted other options, supervised by psychiatrists who applied for and received TGA authorized prescriber status. The split runs roughly 70/30 MDMA to psilocybin; many psychiatrists started with MDMA because the session profile is more predictable. Some patients have since received both compounds sequentially.

The detail that makes the economic case almost impossible to dismiss: with antidepressants, you typically get an initial improvement, then a plateau, then dose escalation or a medication switch. With psychedelic-assisted therapy — two or three maximum sessions, then integration — the remission curve goes up over time, not flat. This pattern, first visible in the NYU and Johns Hopkins trial data, is now replicating in Australian clinical practice.

A data registry at the Australian National University, funded by MMA but operated independently, is collecting real-world evidence from baseline through post-treatment and is expected to publish soon. When it does, health ministries will be looking at something trial data couldn't provide: proof that the results hold outside a controlled environment.

MAPS's economic modelling already put lifetime cost savings above $100,000 USD per patient. That estimate predates the current evidence base.

Not knowing what was impossible turned out to be the strategic advantage

"I said, look, I can also sing. And maybe that was part of it."

Tania de Jong read a Tim Ferriss newsletter in 2015, wrote her accountant a goodbye letter the night before her first psilocybin session in the Netherlands, and eight years later was dancing around her Melbourne kitchen when Australia became the first country on earth to legalize medical psychedelics. She had never taken any drug in her life.

The outsider positioning worked in every direction. She didn't self-censor about what was considered impossible. She flew to a USONA conference in Madison, Wisconsin, mentioned to the founder Bill Linton that she could also sing, and ended up serenading Roland Griffiths. She cold-emailed researchers who had every reason to ignore her. She found out you could donate to spend a week on Ram Dass's property in Maui — and did that, building a network that eventually reached David Nutt and the TGA roadshow.

Insiders in any field are constrained by what they know is difficult. They self-censor before they even ask. They anticipate rejection and build in deference. Tania didn't know what the queue looked like, so she didn't join it.

The credential gap that researchers weaponized against her was the same thing that made her dangerous. No research portfolio to protect. No funding cycle to manage. No professional reputation at risk from failure. Her only interest was patients getting access — and that is a different kind of leverage entirely.

The drug is a rounding error — the cost problem is therapist hours

A full course of psychedelic-assisted therapy in Australia runs about $25,000 AUD — roughly $15,000 USD. Two therapists. Three to four months. Up to three medicine sessions, each lasting five to six hours, plus ongoing integration.

The medicine itself is a tiny fraction of that cost.

This reframes the entire access problem. You're not fighting pharmaceutical pricing. You're fighting labor economics. And the lever for labor economics is group settings — one or two therapists split across four to six patients rather than attending a single person throughout. Not only cheaper: early evidence from better ibogaine clinics suggests outcomes are also better in group environments. Shared integration circles surface insights that don't emerge in solo sessions. Multiple participants means multiple witnesses to each other's experiences.

Several authorized prescribers in Australia have already written group integration into their protocols. Medibank, the country's largest health insurer, now covers near-full treatment costs for eligible gold members. Veterans Affairs and the National Disability Insurance Scheme are both funding access for their respective populations.

The molecule is solved. The delivery model is what needs engineering — and the early data suggests accelerating group protocols is the fastest path to both lower cost and broader access.

The argument that cracked the TGA: not approving this is also a risk

Regulators are trained to ask one question: what could go wrong if we approve this? Tania de Jong forced the TGA to ask a second one.

"If you don't do anything, if you don't reschedule these medicines, that's actually a risk. Because patients who've tried everything, like Franco, might end up taking their own lives."

The TGA had already rejected MMA's application twice at interim stage. They had the science. What they didn't have was a framework that made the harm of inaction visible as a risk category equal to the risks of action.

The 13,000 submissions, Vanessa's testimony, the flood of letters and calls from people begging for access — politicians writing about their constituents, families describing what the wait was costing them — all of it put concrete faces on the casualty count of bureaucratic caution. The committee was not just reviewing an application anymore. It was confronting evidence of what its prior decisions had produced.

Regulators almost never have to account for what their delay costs. The system is designed to weigh the risks of action; the risks of inaction are structurally invisible. Forcing them onto the same ledger rebalances the decision entirely.

Any advocacy campaign where the regulator's default is caution should explicitly calculate and present the cost of inaction. Don't leave that math undone.

What comes next isn't a movement — it's a budget line

The data Australia is generating is something other governments haven't had before: real-world evidence from actual clinical practice, not controlled trials. Sixty to eighty percent remission. Zero serious adverse events across 400 patients. A per-patient lifetime cost-savings case that was already above $100,000 USD before this evidence existed.

The humanitarian argument for psychedelic medicine has been made for decades. What's new is the economic argument — the kind that ends up in health ministry budget reviews rather than bioethics discussions. That's a different audience with different decision criteria, and the Australian registry data is about to speak directly to it.

Australia had to change minds; the countries that follow will only have to read a spreadsheet.

---

Topics: psychedelics, psilocybin, MDMA, mental health, regulatory change, advocacy, Australia, drug policy, PTSD, depression, social entrepreneurship, health policy, clinical trials